By Paul Goldberg

NIH has suspended the facilities that produce investigational compounds for an NCI laboratory engaged in cell therapy production and a National Institute of Mental Health facility producing positron emission tomography materials.

As a result, no new new patients will be enrolled in affected trials until the issues are resolved, NIH said in a press release.

“There is no evidence that any patients have been harmed, but a rigorous clinical review will be undertaken,” the statement reads.

The cell therapy lab is that of Steven Rosenberg, chief of the NCI Surgery Branch and one of the pioneers of immunotherapy.